The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with primary biliary cholangitis (PBC), regardless…
News
CHOLESTASIS
NewsNovel gene mutation is likely cause of newborn’s rare liver disease
A novel mutation in the NR1H4Â gene was the likely cause of progressive familial intrahepatic cholestasis (PFIC) type 5 in a baby girl in Tunisia,…
FATTY LIVER DISEASE
NewsEmerging forever chemical may drive fatty liver disease
Exposure to a human-made chemical called perfluoroheptanoic acid (PFHpA) may increase the risk and severity of fatty liver disease in adolescents with obesity, according…
ALAGILLE SYNDROME
NewsWhy Mexican children with Alagille lag behind in getting proper care
Children in Mexico living with the complex genetic disease Alagille syndrome have limited access to essential care, including confirmatory genetic testing at diagnosis and,…
The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for hepatitis D. The EMA gives…
CHOLANGITIS
NewsThis year, it’s ‘hope into action’ for PSC Awareness Day
Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…
CHOLESTASIS
News2 simple nutrients may be effective new screening tool for ICP
A new study has identified two dietary nutrients, choline and dimethylglycine, as effective potential biomarkers for diagnosing and monitoring intrahepatic cholestasis of pregnancy (ICP).
FATTY LIVER DISEASE
NewsLong-term ketogenic diet may cause fatty liver disease, per mouse study
A long-term ketogenic diet, which favors fats over carbs, may promote weight loss, but it can also cause fatty liver disease and blood sugar…
BILIARY ATRESIA
NewsPotential biliary atresia treatment AX-0810 to enter clinical testing
AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…
Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune hepatitis (AIH). The company has…
Recent Posts
- Biliary atresia, Alagille linked to oral problems in children, young adults
- Top-line Phase 2 trial data for hepatitis C combo therapy expected soon
- Itching drives healthcare costs higher for PBC patients, study finds
- Mystery symptoms and MASH: Your doctor is an ally in solving the puzzle
- Prediction tool helps spot preterm birth risk in ICP twin pregnancies